Ar­cus grabs US rights to a WuXi-built PD-1 as sec­ond wave of check­points builds

West Coast up­start Ar­cus Bio­sciences has bagged its very own PD-1 an­ti­body to take in­to the clin­ic with its im­muno-on­col­o­gy pipeline drugs.

Ar­cus turned to WuXi Bi­o­log­ics and its Chi­nese part­ner Harbin Glo­ria Phar­ma­ceu­ti­cals for re­gion­al North Amer­i­can, Eu­ro­pean and Japan­ese rights to GLS-010. The US biotech is pay­ing $18.5 mil­lion up­front along with a po­ten­tial moth­er­load of de­vel­op­ment and sales mile­stones amount­ing to $816 mil­lion.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER